MARKET

LYRA

LYRA

Lyra Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.57
+0.43
+3.54%
After Hours: 12.57 0 0.00% 16:00 07/10 EDT
OPEN
12.08
PREV CLOSE
12.14
HIGH
12.70
LOW
11.90
VOLUME
74.66K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
10.44
MARKET CAP
162.46M
P/E (TTM)
-9.5582
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LYRA stock price target is 24.33 with a high estimate of 28.00 and a low estimate of 21.00.

EPS

LYRA News

More
Lyra Therapeutics: Advancing An Innovative Solution For Chronic Rhinosinusitis
Seeking Alpha - Article · 3d ago
Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
GlobeNewswire · 5d ago
Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
GlobeNewswire · 06/25 13:00
Lyra Therapeutics To Join Russell 2000, 3000 Indices On Jun. 29
Benzinga · 06/25 12:33
Lyra Therapeutics, e.l.f. Beauty, and Avid Tech See Activist Action
Impactive Capital increased its stake in Avid Technology, a maker of digital-media platforms including Pro Tools. Marathon Partners disclosed a large stake in cosmetics retailer e.l.f. Beauty.
Barrons.com · 06/05 23:25
Lyra Therapeutics reports Q1 results
Lyra Therapeutics (NASDAQ:LYRA): Q1 GAAP EPS of -$18.70. Cash, cash equivalents of $99.2M (including IPO proceeds) Press Release
seekingalpha · 05/29 01:16
Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 05/28 21:05
Lyra Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference
Lyra Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference
Business Wire · 05/28 12:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About LYRA

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases. The Company’s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to locally elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically-naive CRS patients who fail medical management. It has developed LYR-220 for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery.
More

Webull offers kinds of Lyra Therapeutics Inc stock information, including NASDAQ:LYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LYRA stock methods without spending real money on the virtual paper trading platform.